Alpha 2.0
Login Register
» Authors » Jean-Leon Lagrange

Jean-Leon Lagrange

Explore the profile of Jean-Leon Lagrange including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 51
Citations 1189
Followers 0
Related Specialties
Oncology
Radiology
Urology
Top 10 Co-Authors
Sylvie Bastuji-Garin
Philippe Caillet
Elena Paillaud
Veronique Beckendorf
Florence Canoui-Poitrine
Renaud de Crevoisier
Pascal Pommier
Christophe Tournigand
Marie Laurent
Igor Latorzeff
Published In
Int J Radiat Oncol Biol Phys
Bull Cancer
Lancet Oncol
J Clin Oncol
J Gerontol A Biol Sci Med Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
[Events and errors in radiation oncology: Conciliating perspectives to support care]
Haaser T, Constantinides Y, Osman D, Lahmi L, Durdux C, Bourbonne V, et al.
Cancer Radiother . 2024 Oct; 28(6-7):527-533. PMID: 39368919
The term "event" covers a wide range of concrete situations in radiation oncology, from particularly intense radiation-related side effects to the possibility of technical or human error. Although quality procedures...
2.
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial
Orlando V, Drubay D, Lavaud P, Faivre L, Lesaunier F, Delva R, et al.
Clin Genitourin Cancer . 2023 Jun; 21(5):615.e1-615.e8. PMID: 37263910
Introduction: Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases...
3.
The Prognostic Value of Eight Comorbidity Indices in Older Patients with Cancer: The ELCAPA Cohort Study
Canoui-Poitrine F, Segaux L, Benderra M, About F, Tournigand C, Laurent M, et al.
Cancers (Basel) . 2022 May; 14(9). PMID: 35565364
Background: A prognostic assessment is crucial for making cancer treatment decisions in older patients. We assessed the prognostic performance (relative to one-year mortality) of eight comorbidity indices in a cohort...
4.
Predicting Frailty and Geriatric Interventions in Older Cancer Patients: Performance of Two Screening Tools for Seven Frailty Definitions-ELCAPA Cohort
Martinez-Tapia C, Laurent M, Paillaud E, Caillet P, Ferrat E, Lagrange J, et al.
Cancers (Basel) . 2022 Jan; 14(1). PMID: 35008408
Screening tools have been developed to identify patients warranting a complete geriatric assessment (GA). However, GA lacks standardization and does not capture important aspects of geriatric oncology practice. We measured...
5.
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer
Supiot S, Vaugier L, Pasquier D, Buthaud X, Magne N, Peiffert D, et al.
Eur Urol . 2021 Jul; 80(4):405-414. PMID: 34247896
Background: Oligorecurrent pelvic nodal relapse in prostatic cancer is a challenge for regional salvage treatments. Androgen depriving therapies (ADTs) are a mainstay in metastatic prostate cancer, and salvage pelvic radiotherapy...
6.
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
Carrie C, Magne N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange J, et al.
Lancet Oncol . 2019 Oct; 20(12):1740-1749. PMID: 31629656
Background: Radiotherapy is the standard salvage treatment after radical prostatectomy. To date, the role of androgen deprivation therapy has not been formally shown. In this follow-up study, we aimed to...
7.
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial
Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard A, et al.
JAMA Oncol . 2019 Feb; 5(5):623-632. PMID: 30703190
Importance: Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting. Objective: To...
8.
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)
Vaugier L, Palpacuer C, Rio E, Goineau A, Pasquier D, Buthaud X, et al.
Int J Radiat Oncol Biol Phys . 2018 Dec; 103(5):1061-1067. PMID: 30557672
Purpose: Limited pelvic nodal relapse of prostatic cancer is a paramount challenge for locoregional salvage treatments. Salvage whole pelvis radiation therapy as considered in the BLINDED trial is an attractive...
9.
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group
Meyer E, Pasquier D, Bernadou G, Calais G, Maroun P, Bossi A, et al.
Eur J Cancer . 2018 Jun; 98:38-47. PMID: 29864737
Background: Renal cell carcinoma (RCC) is usually considered radioresistant, but stereotactic radiation therapy (SRT) may increase local disease control. This study aimed to assess the benefit of SRT in the...
10.
Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial
Bourgier C, Castan F, Riou O, Nguyen T, Peignaux K, Lemanski C, et al.
Oncotarget . 2018 Apr; 9(21):15757-15765. PMID: 29644007
Background: To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay). Results: HT and RILA...